Blood Purification · 2008 · 27 citations · 0 references
MedicineNephrologyPharmacotherapyDialysisHemodialysisRenal Replacement TherapyAnticoagulant ManagementAnticoagulation In HemodialysisAnticoagulation In Kidney DiseaseChronic HemodialysisDialysis PharmacotherapyIntradialytic ComplicationsAnticoagulant PharmacologyAnticoagulation During DialysisAnticoagulation In Dialysis PatientsAnticoagulation RegimenHeparin AnticoagulationIntradialytic SymptomsParallel Study DesignsRenal Replacement Therapy Anticoagulation
We performed a controlled parallel study comparing the effects of heparin sodium to epoprostenol sodium (prostacyclin sodium, Flolan) during hemodialysis in 30 dialysis patients. Mean fiber bundle volume loss and dialyzer function were similar with both anticoagulation methods. Intradialytic symptoms occurred in 100% of the epoprostenol dialyses and 88% of the heparin dialyses, but only 10/325 epoprostenol and 3/374 heparin dialysis were discontinued prematurely because of symptoms. Long-term hemodialysis with epoprostenol is safe and effective. Epoprostenol may be a suitable alternative to heparin in some dialysis settings.